Viral Vector Manufacturing Market Share, Growth Analysis and Forecast 2033
Viral Vector Manufacturing Market by Type (Retroviral Vectors, Adenoviral Vectors and others), by Disease (Genetic Disorders, Infectious Diseases, and others), by Application (Gene Therapy, Vaccinology)
The?Global Viral Vector Manufacturing Market includes a global opportunity analysis and industry forecasts for the period 2024-2033. The global market was valued at USD $ 2.54 billion in 2022 and is expected to register a CAGR of 17.45% from 2023 to 2032.
Molecular biologists frequently use viral vectors to introduce genetic material into cells. This procedure can be carried out either in cell culture (in vitro) or inside a living creature (in vivo). Specialized molecular processes have evolved in viruses to effectively convey their genomes into the infected cells.
Due to their high transfection efficacy, persistent gene expression, and effective gene transport, viral vectors are frequently utilised to transfer genes into cells. Plasmid DNA is crucial to the medical field as it is a therapeutic component in gene therapy and the creation of vaccine antigens. The increased use of gene therapy to treat viral diseases such as adeno-associated viruses, poxviruses, herpes simplex viruses, and retroviruses is anticipated to increase public acceptability of the treatment, which will support the market growth for viral vector and plasmid DNA production.
Download Premium Sample of This Strategic Report: https://www.quincemarketinsights.com/request-sample-87751
The demand for DNA treatments and cancer research R&D is expected to drive up demand for viral vectors and plasmid DNA manufacturing in the coming years. The main goal of the collaboration was to improve the chromatographic separation of AAV-based vectors by using a variety of AAV variants. As a result, these partnerships should increase the manufacturing effectiveness and scalability of gene therapies, enabling the accessibility of viral vectors on a worldwide scale and opening up profitable business potential. One of the fastest growing fields in advanced medicine is the development of gene therapies using viral vectors and plasmid DNA.
Healthcare organisations are creating DNA vectors for the production of vaccines. The producers of viral vectors and plasmid DNA, whose products are undergoing phase III clinical trials and commercial viral vector production, face numerous difficulties. In terms of productivity, efficiency, stability, and other aspects, many of the existing vector production technologies are insufficient.
Key Players
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
Market Segments
Viral Vector Manufacturing Market, By Type:
In 2021, the Adeno-Associated Virus (AAV) market segment had the biggest market share (18.86%). The rise is attributable to the development of gene therapy treatments for orthopaedic and ophthalmic conditions that are more effective and efficient. AAV usage has recently increased significantly across various therapeutic domains, leading to a large increase in adoption rate over the course of the projection period. One of the major elements promoting their use and these variables are fueling the category market expansion is their demonstrated non-pathogenicity.
Additionally deemed safe are adenoviral vectors. As a result, they are increasingly utilised in a range of research scenarios. ADV vectors are frequently used as vaccines because of their capacity to significantly stimulate humoral and T-cell immune responses. Numerous human cells' host genomes have successfully had genes disrupted in experiments using an adenovirus vector as a CRISPR/Cas9 delivery mechanism.
Viral Vector Manufacturing Market, By Disease:
In 2021, the cancer segment had the biggest market share (37.28%). The market expanded as a result of several research initiatives; an increase in the use of vectors for the creation of cancer medicines; and recent approvals of gene therapy products. Companies currently have a strong pipeline of cancer gene therapy products, which is anticipated to spur market expansion over the course of the projected period.
The effectiveness of viral vector-based therapeutics used to cure genetic abnormalities is the subject of numerous research papers. The use of gene therapy in treating conditions like X-linked chronic granulomatous disease, Duchenne muscular dystrophy (DMD), and Rett syndrome is one such genetic ailment.
领英推荐
Viral Vector Manufacturing Market, By Application:
In 2021, the segment for vaccinations had the biggest market share at 24.76 percent. This is a result of viral vectors' widespread use in vaccine development due to the advantages associated with efficiency. Positives include the capacity to elicit a broad immunological response as well as the safety profiles and simplicity of production.
Additionally, because AAV may express episomal genes without integrating into the host genome, EMA has approved its use in clinical settings. The planning and optimization of vaccination schedules would also encourage the creation of novel vaccines. The use of viral vectors in vaccine development has been spurred by the current COVID-19 virus outbreak.
Prior to the emergence of COVID-19, viral vectors were frequently used for vaccine production. However, because a vaccine against this virus was required, the scientific community was forced to repurpose existing techniques. Non-replicating viral vectors are utilised in COVID-19 viral vector vaccines, and these elements are fueling the segment's market expansion.
Global Viral Vector Manufacturing Market, Based On Regional Analysis:
In 2021, North America held a 48.99 percent share of the worldwide market, dominating it. The existence of a sizable number of centres and institutes involved in the R&D of advanced medicines is one of the key factors that has contributed to the huge share of this regional market. The federal agencies' investments in the region's cell therapy research base are expected to boost the market's expansion in North America. According to estimates, the Asia Pacific region would experience the quickest growth due to factors including the growing patient population, rising R&D spending in this area, and others. Additionally, because the legal environment is less severe in this location, patients from western nations are flying there for stem cell therapy.
Global businesses have also changed their business strategies in this region as a result of the enormous regional population and untapped potential. Additionally, this area provides reasonably priced operating and manufacturing facilities for performing research. These elements are anticipated to significantly contribute to the development of the stem cell sector in this area and accelerate the market's expansion.
Recent Developments In The Global Viral Vector Manufacturing Market:
Some Key Points Of The Viral Vector Manufacturing Market Report Are:
An in-depth global Viral Vector Manufacturing Market analysis by the segments, along with an analysis of trend-based insights and factors.
Major companies operating in the global Viral Vector Manufacturing market, which include FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
Key impact factor analysis across regions that includes analysis, along with the drivers, restraints, opportunities, and challenges that are prevailing in the global Viral Vector Manufacturing Market.
Ask for discount? Do you have any queries? https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-87751
In case you need any specific business requirements, you can mention the same. We can customize the report based on the specific needs of the client.
Contact us:
Quince Market Insights
Phone: +1 208 405 2835
Email:?[email protected]